Anti-IL-4/-13 based therapy in asthma

Bibliography

• Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 2008;372:1107–19
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Adcock IM, Ito K. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur Respir J 2005;25:552–63
   PubMed Web of Science ®Google Scholar
• Gamble J, Stevenson M, McClean E, Heaney LG. The prevalence of non-adherence in difficult asthma. Am J Respir Crit Care Med 2009;180:817–22
   PubMed Web of Science ®Google Scholar
• Berger WE. New approaches to managing asthma: A US perspective. Ther Clin Risk Manag 2008;4:363–79
   PubMedGoogle Scholar
• Shaw DE, Green RH, Bradding P. Asthma exacerbations: prevention is better than cure. Ther Clin Risk Manag 2005;1(4):273–7
   PubMedGoogle Scholar
• Pelaia G, Vatrella A, Maselli R. The potential of biologics for the treatment of asthma. Nat Rev Drug Discov 2012;11:958–72
   PubMed Web of Science ®Google Scholar
• Walsh GM. An update on emerging drugs for asthma. Expert Opinion Emerg Drugs 2012;17(1):37–42
   PubMed Web of Science ®Google Scholar
• Wills-Karp M, Luyimbazi J, Xu X, et al. Interleukin-13: central mediator of allergic asthma. Science 1998;282:2258–60
   PubMed Web of Science ®Google Scholar
• Berry MA, Parker D, Neale N, et al. Sputum and bronchial submucosal IL-13 expression in asthma and eosinophilic bronchitis. J Allergy Clin Immunol 2004;114:1106–9
   PubMed Web of Science ®Google Scholar
• Saha SK, Berry MA, Parker D, et al. Increased sputum and bronchial biopsy IL-13 expression in severe asthma. J Allergy Clin Immunol 2008;121:685–91
   PubMed Web of Science ®Google Scholar
• Walsh GM. Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD. Curr Opin Investig Drugs 2010;11:1305–12
   PubMed Web of Science ®Google Scholar
• May R, Monk P, Cohen E, et al. Preclinical development of CAT-354, an IL-13-neutralising antibody, for the treatment of severe uncontrolled asthma. Br J Pharmacol 2012;166:177–93
   PubMed Web of Science ®Google Scholar
• Piper E, Brightling C, Niven R Oh C, et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J 2013;4:330–8
   Web of Science ®Google Scholar
• Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011;365:1088–98
   PubMed Web of Science ®Google Scholar
• Jia G, Erickson RW, Choy DF Mosesova S, Bronchoscopic Exploratory Research Study of Biomarkers in Corticosteroidrefractory Asthma (BOBCAT) Study Group. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol 2012;130:647–54
   PubMed Web of Science ®Google Scholar
• Noonan M, Korenblat P, Mosesova S, et al. Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids. J Allergy Clin Immunol 2013;132(3):567–74
   PubMed Web of Science ®Google Scholar
• Diamant Z, Gauvreau GM, Cockcroft DW, et al. Inhaled allergen bronchoprovocation tests. J Allergy Clin Immunol 2013;132:1045–55
   PubMed Web of Science ®Google Scholar
• Scheerens H, Arron JR, Zheng Y, et al. The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge. Clin Exp Allergy 2014;44:38–46
   PubMed Web of Science ®Google Scholar
• Jiang H, Harris MB, Rothman P. IL-4/IL-13 signalling beyond JAK/STAT. J Allergy Clin Immunol 2000;105:1063–70
   PubMed Web of Science ®Google Scholar
• Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013;368(26):2455–66
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Inhibiting IL-4 and IL-13 in difficult-to-control asthma. N Engl J Med 2013;368(26):2511–13
   PubMed Web of Science ®Google Scholar
• Arron JR, Choy DF, Scheerens H, Matthews JG. Noninvasive biomarkers that predict treatment benefit from biologic therapies in asthma. Ann Am Thorac Soc 2013;10(Suppl):S206–13
   PubMedGoogle Scholar
• Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009;180:59–99
   PubMed Web of Science ®Google Scholar
• Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 2014;371(2):130–9
   PubMed Web of Science ®Google Scholar
• Holgate ST. Innate and adaptive immune responses in asthma. Nat Med 2012;18:673–83
   PubMed Web of Science ®Google Scholar
• Aryan Z, Holgate ST, Radzioch D, Rezaei N. A new era of targeting the ancient gatekeepers of the immune system: toll-like agonists in the treatment of allergic rhinitis and asthma. Int Arch Allergy Immunol 2014;164(1):46–63
   PubMed Web of Science ®Google Scholar